본문으로 건너뛰기
← 뒤로

Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database.

1/5 보강
Journal for immunotherapy of cancer 📖 저널 OA 99.7% 2022: 3/3 OA 2023: 1/1 OA 2024: 13/13 OA 2025: 143/143 OA 2026: 153/154 OA 2022~2026 2026 Vol.14(3)
Retraction 확인
출처

Li L, Ren F, Liu Z, Tian X, Zhang H, Wang G

📝 환자 설명용 한 줄

This research analyzes the global landscape of clinical trials focusing on therapies targeting the Nectin cell adhesion molecule 4 (Nectin-4) across various malignancies, using data from the Trialtrov

이 논문을 인용하기

↓ .bib ↓ .ris
APA Li L, Ren F, et al. (2026). Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database.. Journal for immunotherapy of cancer, 14(3). https://doi.org/10.1136/jitc-2025-014345
MLA Li L, et al.. "Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database.." Journal for immunotherapy of cancer, vol. 14, no. 3, 2026.
PMID 41807035 ↗

Abstract

This research analyzes the global landscape of clinical trials focusing on therapies targeting the Nectin cell adhesion molecule 4 (Nectin-4) across various malignancies, using data from the Trialtrove database. Analysis of 136 interventional trials reveals a rapidly expanding field dominated by antibody-drug conjugates, particularly in urothelial carcinoma, with significant activity in combination regimens and diverse therapeutic modalities under exploration. These findings emphasize the substantial translational potential of Nectin-4 and highlight key trends shaping its future clinical development.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

📖 전문 본문 읽기 PMC JATS · ~11 KB · 영문

Supplementary material

Supplementary material
10.1136/jitc-2025-014345online supplemental file 1

출처: PubMed Central (JATS). 라이선스는 원 publisher 정책을 따릅니다 — 인용 시 원문을 표기해 주세요.

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기